Regen Biopharma INC (RGBPP) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Nov 13, 2025
• Regen BioPharma Files 8-K: Material Agreement & Equity Sales — Oct 3, 2025 Risk: medium
  On October 2, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Regen BioPharma Reports Unregistered Equity Sales — Sep 19, 2025 Risk: medium
  Regen BioPharma Inc. filed an 8-K on September 19, 2025, reporting unregistered sales of equity securities as of September 15, 2025. The filing does not specify
• Regen BioPharma Files 8-K for Material Agreement — Aug 7, 2025 Risk: medium
  Regen BioPharma Inc. announced on August 5, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equit
• Regen BioPharma Inc. Files 8-K with Material Agreements — Aug 1, 2025 Risk: medium
  On July 28, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fi
• Regen BioPharma Reports Unregistered Equity Sales — Jun 11, 2025 Risk: medium
  Regen BioPharma Inc. filed an 8-K on June 11, 2025, reporting unregistered sales of equity securities. The filing details events that occurred on June 10, 2025,
• Regen BioPharma Changes Auditors — Apr 7, 2025 Risk: medium
  Regen BioPharma Inc. announced on March 31, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public ac
• Regen BioPharma Files 8-K on Financials — Nov 29, 2024 Risk: low
  Regen BioPharma Inc. filed an 8-K on November 29, 2024, reporting on its financial condition and results of operations as of September 30, 2024. The filing deta
• Regen BioPharma to Acquire 03 Life Sciences — Sep 18, 2024 Risk: medium
  Regen BioPharma Inc. announced on September 18, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of 03 L
• Regen BioPharma Inc. Files 8-K for Material Definitive Agreement — Sep 13, 2024 Risk: medium
  Regen BioPharma Inc. entered into a material definitive agreement on September 4, 2024. The company, incorporated in Nevada with its principal executive offices
• Regen BioPharma Changes Independent Accountant — May 29, 2024 Risk: medium
  Regen BioPharma Inc. announced on May 28, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public acco
• Regen BioPharma Files 8-K with Corporate Updates — May 23, 2024 Risk: low
  Regen BioPharma Inc. filed an 8-K on May 23, 2024, reporting an event on May 20, 2024. The filing indicates changes to its Articles of Incorporation or Bylaws,
• Regen BioPharma Changes Auditors — May 10, 2024 Risk: low
  Regen BioPharma Inc. announced on May 10, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public acco
• Regen BioPharma Files 8-K: Material Agreement & Equity Sales — Apr 29, 2024 Risk: medium
  Regen BioPharma Inc. entered into a material definitive agreement on April 26, 2024. The company also reported on unregistered sales of equity securities and ot
• Regen BioPharma: Emerging Growth Co. Opts Out of Extended Accounting Transition — Feb 9, 2024 Risk: low
  Regen BioPharma Inc. filed an 8-K on February 9, 2024, reporting an 'Other Events' item from February 7, 2024. The filing indicates the company is an 'emerging

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX